Tagged with Merck,

Korea Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for companies like Merck to utilize local partnerships.   We are in the process of preparing launches of our new molecules…

Hong Kong Merck Hong Kong’s Hee-sun Lee gives her first impressions of the Hong Kong market, her main priorities, upcoming product launches and tapping into the territory’s R&D ecosystem. Hee-sun, having joined Merck Pharmaceutical Hong Kong in February 2018 from the South Korean affiliate, what are your first impressions of the market…

Portugal Pedro Moura is the first Portuguese managing director of Merck in Portugal, taking on the role in September 2017 after a stint in HQ in Darmstadt, Germany. Moura discusses Merck’s global vision, new and exciting products coming soon to the Portuguese market and the importance of collaborative partnerships across the…

Canada At the 350th anniversary of the company, Gaby Murphy, EMD Serono’s managing director, gives an insight into the turning point for the affiliate in 2017 with three new Health Canada approvals. Over the last few months, we have witnessed significant changes within the Canadian pharmaceutical landscape, especially in terms of…

Baltics Evija Buksa, general manager at Merck in Latvia, explains the strong history of Merck in the country as well as its key role in participating in the discussions to shape the Latvian healthcare system. Could you please start by introducing Merck in Latvia and the strategic significance of the local…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.

Merck Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal with NHS England for its innovative new multiple sclerosis (MS) treatment, Mavenclad and how this deal stands as a new…

Canada Chirfi Guindo, president and managing director of Merck Canada, highlights the stunning transformation that has led to a revitalized new Merck affiliate, the innovation opportunities Canada’s fragmented and diverse health systems offers, and the importance of greater collaboration and dialogue between all stakeholders within Canada’s healthcare and innovation ecosystem. Three…

Bulgaria Ana Tsakova, managing director at Merck Bulgaria, emphasizes the duty of the industry to raise the bar of treatment quality in the country and shows the commitment of Merck in this regard to collaborate with both physicians and patients in key therapeutic areas such as oncology, fertility, multiple sclerosis, diabetes,…

Brazil Guilherme Maradei, managing director of Merck Brazil and general manager Biopharma, documents the eye-catching growth that the Brazilian affiliate has been experiencing over the past two years and provides insights into the outstanding footprint of the company in Brazil as well as its remarkable ambitions and achievements when it comes…

Tunisia Karim Bendhaou, president of Merck North West Africa, discusses the region-specific strategies he has instigated, how a country like Tunisia would be well advised to focus its resources on e-health rather than production, and highlights the numerous initiatives that Merck has set up to develop healthcare access in Africa. Where…

Colombia Eduardo Obraczka, managing director at Merck Colombia, shares his appreciation for the flexibility of the Colombian talent pool, while explaining Merck’s successful strategy that has led to the impressive growth of the organization in the country, and highlights how Merck is continuously fostering an innovative and dynamic environment. How does…